Abstract: The present invention relates to a method for engineering an immunoglobulin comprising a variable domain and at least one modification in at least two structural loops of said immunoglobulin and determining the binding of said immunoglobulin to an epitope of an antigen, wherein the unmodified immunoglobulin does not significantly bind to said epitope, comprising the steps of: providing a nucleic acid encoding an immunoglobulin comprising at least two structural loops, modifying at least one nucleotide residue of each of said structural loops, transferring said modified nucleic acid in an expression System, expressing said modified immunoglobulin, contacting the expressed modified immunoglobulin with an epitope, and determining whether said modified immunoglobulin binds to said epitope, immunoglobulins produced by such a method and libraries of immunoglobulins.

Abstract: The invention relates to a cytotoxic modular antibody with a molecular weight of up to 60 kD, specifically binding to a cell surface target with a binding affinity of Kd<10?8 M, a method of producing such antibody and its use as a therapeutic.

Abstract: The present invention relates to a method for engineering an immunoglobulin comprising a variable domain and at least one modification in at least two structural loops of said immunoglobulin and determining the binding of said immunoglobulin to an epitope of an antigen, wherein the unmodified immunoglobulin does not significantly bind to said epitope, comprising the steps of: providing a nucleic acid encoding an immunoglobulin comprising at least two structural loops, modifying at least one nucleotide residue of each of said structural loops, transferring said modified nucleic acid in an expression System, expressing said modified immunoglobulin, contacting the expressed modified immunoglobulin with an epitope, and determining whether said modified immunoglobulin binds to said epitope, immunoglobulins produced by such a method and libraries of immunoglobulins.

Abstract: The present application relates to a method of preparing a genetic package displaying oligomers of modular antibody domains binding to a target and to a scaffold ligand as well as to vectors and libraries of genetic packages produced thereby. The invention further relates to methods of selecting suitable linker sequences for use in such oligomer display.

Abstract: The present application relates to a method of preparing a genetic package displaying oligomers of modular antibody domains binding to a target and to a scaffold ligand as well as to vectors and libraries of genetic packages produced thereby. The invention further relates to methods of selecting suitable linker sequences for use in such oligomer display.

Abstract: The invention relates to a cytotoxic;modular antibody with a molecular weight of up to 6OkD, specifically binding to a cell surface target with a binding affinity of Kd<10?8 M, a method of producing such antibody and its use as a therapeutic.

Abstract: The invention relates to a cytotoxic modular antibody with a molecular weight of up to 60 kD, specifically binding to a cell surface target with a binding affinity of Kd<10?8 M, a method of producing such antibody and its use as a therapeutic.

Abstract: The present invention relates to a method for engineering an immunoglobulin comprising a variable domain and at least one modification in at least two structural loops of said immunoglobulin and determining the binding of said immunoglobulin to an epitope of an antigen, wherein the unmodified immunoglobulin does not significantly bind to said epitope, comprising the steps of: providing a nucleic acid encoding an immunoglobulin comprising at least two structural loops, modifying at least one nucleotide residue of each of said structural loops, transferring said modified nucleic acid in an expression system, expressing said modified immunoglobulin, contacting the expressed modified immunoglobulin with an epitope, and determining whether said modified immunoglobulin binds to said epitope, immunoglobulins produced by such a method and libraries of immunoglobulins.

Abstract: A method for engineering an immunoglobulin having a variable domain and at least one modification in at least two structural loops of the immunoglobulin and determining the binding of the immunoglobulin to an epitope of an antigen, where the unmodified immunoglobulin does not significantly bind to said epitope, comprising the steps of providing a nucleic acid encoding an immunoglobulin having at least two structural loops, modifying at least one nucleotide residue of each of the structural loops, transferring the modified nucleic acid in an expression system, expressing the modified immunoglobulin, contacting the expressed modified immunoglobulin with an epitope, and determining whether the modified immunoglobulin binds to the epitope.

Abstract: The invention relates to a cytotoxic modular antibody with a molecular weight of up to 6 OkD, specifically binding to a cell surface target with a binding affinity of Kd<10?8 M, a method of producing such antibody and its use as a therapeutic.

Abstract: The present application relates to a method of preparing a genetic package displaying oligomers of modular antibody domains binding to a target and to a scaffold ligand as well as to vectors and libraries of genetic packages produced thereby. The invention further relates to methods of selecting suitable linker sequences for use in such oligomer display.

Abstract: The present invention relates to a method of preparing a genetic package displaying oligomers of modular antibody domains binding to a target and to a scaffold ligand as well as to vectors and libraries of genetic packages produced thereby. The invention further relates to methods of selecting suitable linker sequences for use in such oligomer display.

Abstract: The invention relates to a cytotoxic modular antibody with a molecular weight of up to 6OkD, specifically binding to a cell surface target with a binding affinity of Kd<10?8 M, a method of producing such antibody and its use as a therapeutic.

Abstract: The invention relates to a cytotoxic modular antibody with a molecular weight of up to 6 OkD, specifically binding to a cell surface target with a binding affinity of Kd<10?8 M, a method of producing such antibody and its use as a therapeutic.

Abstract: The invention relates to a monoclonal antibody or derivative or fragment thereof that is derived from a parental monoclonal antibody, that recognizes the Lewis Y antigen, characterized in that the Fc region or region equivalent to the Fc region of said antibody or derivative or fragment thereof carries a bi-sected hybrid type N-glycosylation pattern and that said antibody shows at least 10 fold increased ADCC and at least 10% reduced CDC activity.

Abstract: The invention relates to a cytotoxic modular antibody with a molecular weight of up to 6 OkD, specifically binding to a cell surface target with a binding affinity of Kd<10?8 M, a method of producing such antibody and its use as a therapeutic.

Abstract: The invention relates to a monoclonal antibody or derivative or fragment thereof that is derived from a parental monoclonal antibody, that recognizes the Lewis Y antigen, characterized in that the Fc region or region equivalent to the Fc region of said antibody or derivative or fragment thereof carries a bi-sected hybrid type N-glycosylation pattern and that said antibody shows at least 10 fold increased ADCC and at least 10% reduced CDC activity.

Abstract: The present invention relates to a method of preparing a genetic package displaying oligomers of modular antibody domains binding to a target and to a scaffold ligand as well as to vectors and libraries of genetic packages produced thereby. The invention further relates to methods of selecting suitable linker sequences for use in such oligomer display.

Abstract: The invention relates to a monoclonal antibody, or fragment of the antibody, that is derived from a parental monoclonal antibody, that recognizes the Lewis Y antigen, characterized in that the Fc region of the antibody, or fragment of the antibody, carries a bi-sected hybrid type N-glycosylation pattern and that the antibody shows at least 10 fold increased ADCC and at least 10% reduced CDC activity.

Abstract: The present invention relates to a method for engineering an immunoglobulin comprising a variable domain and at least one modification in at least two structural loops of said immunoglobulin and determining the binding of said immunoglobulin to an epitope of an antigen, wherein the unmodified immunoglobulin does not significantly bind to said epitope, comprising the steps of: providing a nucleic acid encoding an immunoglobulin comprising at least two structural loops, modifying at least one nucleotide residue of each of said structural loops, transferring said modified nucleic acid in an expression System, expressing said modified immunoglobulin, contacting the expressed modified immunoglobulin with an epitope, and determining whether said modified immunoglobulin binds to said epitope, immunoglobulins produced by such a method and libraries of immunoglobulins.